SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: The first use of CRISPR/Cas9 technology in epilepsy was reported in 2016 to generate a loss of function SCN1A mutation in human iPSCs to gain insight into Dravet syndrome [114].